Cancer
Conditions
Keywords
Discrete Choice Experiment
Brief summary
To provide timely access to new treatments, some eligible drugs can be approved despite uncertainty surrounding the level of clinical benefit they offer patients. It is not currently known if (and under which circumstances) people would prefer to wait to access some new drugs in exchange for greater certainty surrounding their clinical benefit. This study aims to elicit the preferences of people in the US with experience of cancer for wait times and clinical uncertainty of new drugs. To elicit this information, in a survey format, respondents will be presented with a hypothetical scenario and asked to state their preferences for new treatments, each with different attributes.
Interventions
OTHERDiscrete Choice Experiment (DCE)
DCE survey experiment
Sponsors
London School of Economics and Political Science
Study design
Observational model
OTHER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Individuals previously or currently diagnosed with any type of cancer. * Individuals with immediate family members previously or currently diagnosed with any type of cancer.
Exclusion criteria
* Individuals without previous or current diagnosis with any type of cancer (themselves or immediate family members).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Preferences for treatment attributes and trade-offs between attributes. | Through study completion, an average of 4-8 weeks. | Preferences for different treatment attributes (including clinical uncertainty and wait time), and trade-offs between these, using a study-specific Discrete Choice Experiment (DCE) Questionnaire. Preferences are measured on relative utility scale (arbitrary units, no min/max). Utility indicates preference e.g., higher values are more preferred (better). |
Countries
United Kingdom
Outcome results
None listed